Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Net Income | -857.00K | -- | -5.31M | ||
| Total Depreciation and Amortization | 0.00 | -- | 11.00K | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 159.00K | -- | 3.68M | ||
| Change in Net Operating Assets | -19.00K | -- | 719.00K | ||
| Cash from Operations | -717.00K | -- | -897.00K | ||
| Capital Expenditure | -- | -- | 0.00 | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | 0.00 | ||
| Total Debt Issued | 2.67M | -- | 750.00K | ||
| Total Debt Repaid | -64.00K | -- | -9.00K | ||
| Issuance of Common Stock | -- | -- | 150.00K | ||
| Repurchase of Common Stock | -1.86M | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | 750.00K | -- | 891.00K | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 33.00K | -- | -6.00K | ||